

Raoul Charles Coombes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4698997/publications.pdf>

Version: 2024-02-01

23
papers

2,029
citations

623188

14
h-index

642321

23
g-index

23
all docs

23
docs citations

23
times ranked

2959
citing authors

#	ARTICLE	IF	CITATIONS
1	Survival and safety of exemestane versus tamoxifen after 2â€“3 years' tamoxifen treatment (Intergroup) Tj ETQq1 1 0.784314 rgBT /Ov	6.3	805
2	Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence. <i>Clinical Cancer Research</i> , 2019, 25, 4255-4263.	3.2	281
3	Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance. <i>Oncogene</i> , 2016, 35, 990-1002.	2.6	167
4	Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer. <i>Oncogene</i> , 2017, 36, 2286-2296.	2.6	135
5	FOXM1 targets NBS1 to regulate DNA damage-induced senescence and epirubicin resistance. <i>Oncogene</i> , 2014, 33, 4144-4155.	2.6	109
6	Myocardial MiR-30 downregulation triggered by doxorubicin drives alterations in Î²-adrenergic signaling and enhances apoptosis. <i>Cell Death and Disease</i> , 2015, 6, e1754-e1754.	2.7	98
7	NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 581-590.	1.1	76
8	SUMOylation inhibits FOXM1 activity and delays mitotic transition. <i>Oncogene</i> , 2014, 33, 4316-4329.	2.6	75
9	The miR-106b~1/25 cluster promotes bypass of doxorubicin-induced senescence and increase in motility and invasion by targeting the E-cadherin transcriptional activator EP300. <i>Cell Death and Differentiation</i> , 2014, 21, 462-474.	5.0	75
10	High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial. <i>Annals of Oncology</i> , 2005, 16, 726-734.	0.6	44
11	Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)â€”a randomised controlled trial of exemestane versus continued tamoxifen after 2â€“3 years tamoxifen. <i>Annals of Oncology</i> , 2010, 21, 498-505.	0.6	34
12	New IR imaging modalities for cancer detection and for intra-cell chemical mapping with a sub-diffraction mid-IR s-SNOM. <i>Faraday Discussions</i> , 2016, 187, 539-553.	1.6	31
13	miR-106b~25 cluster regulates multidrug resistance in an ABC transporter-independent manner via downregulation of EP300. <i>Oncology Reports</i> , 2016, 35, 1170-1178.	1.2	22
14	Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer. <i>Nature Communications</i> , 2022, 13, .	5.8	19
15	An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study). <i>Annals of Oncology</i> , 2013, 24, 924-930.	0.6	13
16	Zinc stable isotopes in urine as diagnostic for cancer of secretory organs. <i>Metallomics</i> , 2021, 13, .	1.0	12
17	Prognostic and predictive value of ERÎ²1 and ERÎ²2 in the Intergroup Exemestane Study (IES)â€”first results from PathIES. <i>Annals of Oncology</i> , 2015, 26, 1890-1897.	0.6	11
18	Longitudinal whole-exome sequencing of cell-free DNA for tracking the co-evolutionary tumor and immune evasion dynamics: longitudinal data from a single patient. <i>Annals of Oncology</i> , 2021, 32, 681-684.	0.6	6

#	ARTICLE	IF	CITATIONS
19	Prevalence of ctDNA in early screen-detected breast cancers using highly sensitive and specific dual molecular barcoded personalised mutation assays. <i>Annals of Oncology</i> , 2021, 32, 1057-1060.	0.6	4
20	Epirubicin dose and sequential hormonal therapyâ€™Mature results of the HMFEC randomised phase III trial in premenopausal patients with node positive early breast cancer. <i>European Journal of Cancer</i> , 2016, 60, 146-153.	1.3	3
21	Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 169-178.	1.1	3
22	Prospective meta-analysis of randomised trials of cyclophosphamide, methotrexate & fluorouracil (CMF) vs fluorouracil, epirubicin & cyclophosphamide (FEC) chemotherapy in early breast cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 592-592.	0.8	3
23	Endocrine and clinical responses to steroid sulfatase inhibition: Results from the first phase I trial in women with breast cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 580-580.	0.8	3